Latest news with #Cullinan
Yahoo
5 hours ago
- Business
- Yahoo
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028 Company to host conference call today at 4:30 pm ET CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; 'Cullinan'), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into an agreement with Genrix Bio for a global (ex-Greater China), all indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T cell engager. Velinotamig has demonstrated potential best-in-class efficacy at the Phase 2 target dose in nearly 50 patients with relapsed/refractory (r/r) multiple myeloma (MM). Cullinan will develop velinotamig in autoimmune diseases. 'We believe T cell engagers represent the next wave of innovation in autoimmune diseases, and we are excited to build upon our core T cell engager expertise and extensive KOL relationships to develop another potential best-in-class, clinical-stage program. Accumulated data supports BCMA as a promising target in autoimmune diseases, offering a precise and potentially disease-modifying approach by eliminating the entirety of the self-reactive plasma cells that result in certain autoimmune diseases, especially those diseases driven by long-lived plasma cells,' said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics. 'Adding a BCMAxCD3 bispecific T cell engager to our pipeline complements our rapid global clinical development of CLN-978, enabling us to address the needs of more patients across a broader range of autoimmune diseases than with either molecule alone.' Genrix plans to initiate a Phase 1 study in China by the end of this year in patients with autoimmune diseases. Cullinan intends to use the data generated to accelerate global clinical development of the program. Following the completion of the Genrix Bio Phase 1 study, Cullinan will conduct all further development of velinotamig in autoimmune diseases. 'With our planned Phase 1 study of velinotamig in autoimmune diseases, we will be able to quickly leverage our experience in autoimmune diseases to complete the study in China expeditiously,' said Dr. Liu Zhigang, Chairman, Chief Executive Officer, and Chief Science Officer of Genrix Biopharmaceutical 'Cullinan is a proven leader in developing T cell engagers and we are confident in the company's ability to carry the program forward to address the needs of patients with autoimmune diseases.' Under the agreement, Cullinan will pay Genrix Bio an upfront license fee of $20 million for exclusive rights to develop and commercialize velinotamig in all disease areas globally outside of Greater China. In the future, Genrix will also be eligible to receive up to $292 million in development and regulatory milestones plus up to an additional $400M in sales-based milestones, as well as tiered royalties from mid-single digits up to the mid- teens on potential ex-Greater China net sales. Importantly, with refinement of the clinical oncology pipeline, Cullinan reiterates its existing guidance to have cash resources into 2028 based on its current operating plan. Cullinan Therapeutics Conference Call Information Cullinan Therapeutics will host a conference call today, June 4, at 4:30 pm ET. Investors, analysts and the general public are invited to listen to a live webcast of the call. A link to join the call and to find related materials will be available under the Events and Presentations section of the Company's investor relations website at About Velinotamig Velinotamig is a bispecific antibody that can simultaneously bind to the BCMA and CD3 antigens, redirecting cytotoxic T cells to target BCMA-expressing cells. Velinotamig has high affinity for BCMA and lower affinity for CD3. Affinity for BCMA is two orders of magnitude higher than for CD3, ensuring that the bispecific antibody recruits and activates T cells while minimizing non-specific T cell activation and reducing the toxicity mediated by the CD3 antibody. Genrix Bio received approval from the National Medical Products Administration (NMPA) in January 2022 to conduct clinical trials for the indication of multiple myeloma. Velinotamig received Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) for the treatment of relapsed and refractory multiple myeloma. About Cullinan Therapeutics Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan's portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at and follow us on LinkedIn and X. About Genrix Bio Genrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. With antibody drug R&D centers in Beijing, Shanghai, and Chongqing, we are committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Our capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Upholding the philosophy of "to deliver affordable and reliable new medicines for patients," we strive to address the clinical needs of a wider population. Learn more about Genrix Bio at Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan's beliefs and expectations regarding the potential benefits of, and plans relating to, the license agreement between Cullinan and Genrix Bio, including anticipated milestone payments under the license agreement, as well as royalties on net sales; the therapeutic potential of velinotamig; the timing of planned clinical development of velinotamig; our expectations regarding our cash resources; and other statements that are not historical facts. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'hope,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'should,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the success of our clinical trials and preclinical studies; risks related to our ability to protect and maintain our intellectual property position; risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption 'Risk Factors' in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither Cullinan nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Contacts: InvestorsNick Smith+1 401.241.3516nsmith@ Media Rose Weldon+1 215.801.7644rweldon@
The South African
27-05-2025
- General
- The South African
Seven-hour power outage to affect parts of Tshwane on Thursday
Due to an emergency supply interruption, Eskom has scheduled a seven-hour power outage which is set to affect Cullinan in Tshwane. The maintenance is scheduled for Thursday, 29 May from 11:00 – 18:00. The power utility said there will be emergency electricity supply interruption due to maintenance that will be conducted on the distribution network. The maintenance will affect the following customers: Butjani Lodge Lama-Lama Game Reserve Loodswaai Game Lodge Leeuwfontein Provincial Nature Reserve Moloto North Savanna Game Farm Wagondrift Lodge, Spa and Game Farm Similarly, Eskom said there will be an electricity supply disruption in Soweto, due to maintenance that will be conducted on the distribution network. 'The power outage will affect customers in parts of Braamfischer Phases 1, 2 and Doornkop Blocks 1, 2, 3, 4, 5, 6 and 7 on Friday, 30 May, from 9:00 – 18:00. The interruption of electricity is necessary to perform essential maintenance on our distribution power lines,' the power utility said. In the interest of safety, Eskom said customers should treat all electrical appliances as live at all times during the planned maintenance. 'Eskom apologises for any inconvenience that may be caused by this maintenance,' the power utility said. In addition, Eskom said that if circumstances are beyond its control, the planned power outage in Gauteng may not proceed as communicated. Let us know by leaving a comment below, or send a WhatsApp to 060 011 021 1. Subscribe to The South African website's newsletters and follow us on WhatsApp, Facebook, X, and Bluesky for the latest news.
Motor 1
20-05-2025
- Automotive
- Motor 1
The Rolls-Royce Cullinan Is Even Better As a Black Badge: Video Review
Umbrella in the door, Spirit of Ecstasy on the hood, stars in the headliner—the list goes on. Almost all Rolls-Royce reviews focus on these elements first, which, yes, do make the cars from Goodwood feel special. But focusing on those features risks being a bit limiting. Well, this review is different. I'm driving the Cullinan Series II , an updated version of the brand's first luxury SUV. Even better is the fact that this is the Black Badge model, which, for those who don't know, is the name given to the brand's most daring vehicles. So if a standard Rolls-Royce is Dr. Jekyll, the Black Badge is his Mr. Hyde. Of course, don't expect too much cheekiness—we're still talking about a Rolls-Royce . Imagine this Cullinan is a gentleman who, at the end of the evening, loosens his tie or takes it off altogether as he's ready for the night on the town. Rolls-Royce Cullinan Black Badge Series II: Monumental Photo by: Rolls-Royce In front of me is an SUV that is over 18 feet long, 6 feet wide, and as tall as a van. The Cullinan Series 2 commands respect, even amongst those who may not immediately recognize the brand. Although that might be difficult given the black Spirit of Ecstasy protruding from the hood. Nothing stops customers from ordering this SUV in crystal, gold, or any other ultra-expensive hue. And the black chrome extends everywhere. The new, low-swept headlights are more modern, but I preferred the shape of the lower air intakes how they were previously. The exhaust tips are new, as are the 23-inch wheels. But with the Black Badge, it's not just about looks. The 6.75-liter V-12 here produces 600 horsepower and 664 pound-feet of torque, and it takes 4.2 seconds for this SUV to reach 60 miles per hour. That's surprising when considering that this SUV weighs over 2.7 tons. Photo by: Rolls-Royce Photo by: Rolls-Royce On the Black Badge model, the pedal is more sensitive, and the V-12 is louder thanks to a repositioning of the sound-absorbing materials. Although there's no Sport mode, the eight-speed gearbox has a 'Low' mode that increases the responsiveness. All-wheel drive and four-wheel steering ensure roadholding, yet with its light steering, shock absorbers soften the ride quality to perfection, electronically adjusting themselves with no hint of sportiness in the Cullinan Black Badge's driving dynamics. But one thing's clear: It's not designed to 'make time.' It's built to resist it. Perfection may be unattainable, but the Rolls-Royce Cullinan Black Badge gets close. All it takes to get there is half a million dollars. Black Badge, Bespoke, Coachbuild: The Soul Of Rolls-Royce Photo by: Rolls-Royce Black Badge is for customers who want something less formal. Debuting in 2016, Black Badge is aimed at a younger audience who prefers driving their cars. But, as mentioned, it's not enough to just paint everything black: The performance is enhanced and the materials are more modern. With the Bespoke program, a further level of refinement is reached. In fact, it is the most advanced and detailed customization system in the entire automotive landscape, offering customers the opportunity to create some truly unique and even unrepeatable cars. Photo by: Rolls-Royce For example, one customer requested that the wooden inserts in the cabin be made from his favorite tree in his garden, while another commissioned a starry night interior that replicated the constellation visible on his wedding day. That kind of detail. The personalization process begins at the Rolls-Royce Private Office in the UK, a dedicated space where clients collaborate with designers and craftsmen to bring their vision to life. Here, every element of the car is customizable: From the paintwork, with over 40,000 shades to choose from, to the interior, where you can choose from a wide range of leathers, fine woods, and handcrafted details. I got the chance to visit this magical place where these Rolls-Royce models come to life. Of course, you can't forget the Coachbuild program. That's the exclusive service that allows customers to design completely new vehicles, such as the four cars in the Droptail family—one of which remains a secret. More From Rolls-Royce Rolls-Royce Spectre Black Badge: This Is It Every V-12-Powered Car You Can Still Buy in 2025 Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
NDTV
17-05-2025
- Sport
- NDTV
"Not A Loss For India...": South Africa Great Delivers Cut-Throat 'Honest' Verdict On Rohit Sharma's Retirement
Rohit Sharma announced his retirement from Test cricket ahead of India's five-match Test series in England in June. Amid reports that Rohit was set to be removed from captaincy, the 37-year-old announced his retirement from the longest format of the game. Rohit's retirement came after a disastrous tour of Australia, during which he managed just 31 runs in five innings. South Africa great Daryll Cullinan has spoken strongly on Rohit's retirement, however, stating that India will not miss him much in Tests. Rohit retired having made 4,301 runs in 67 Test matches at an average of over 40, as well as winning 12 out of his 24 Tests as captain of India. However, Cullinan felt that his retirement from Test cricket was long overdue. "Rohit's retirement was probably long overdue in terms of test cricket away from India. Let's be honest about it," Cullinan said, speaking to Hindustan Times. "He hasn't really been the player that he throughout his career has been at home and we saw reluctance from him in recent Australian series to really take it on and lead from the front. So I don't see that as being a loss for India at all," Cullinan added. Prior to the 2024/25 Border-Gavaskar Trophy series, Rohit had also had a rough patch with the bat during the Test series against New Zealand. Rohit's last good run of form with the bat in Test cricket came when India hosted England in early 2024. Rohit slammed more than 400 runs with the bat across five Tests in that series. Rohit's retirement has left India with a big hole to fill for the England series in terms of the captain, and not only with the bat. Sources have pointed that Shubman Gill is set to take over as India's new Test captain. Listen to the latest songs, only on
Forbes
13-05-2025
- Business
- Forbes
The 10.3-Carat ‘Mediterranean Blue' Diamond Fetches $21.5 Million
'The Mediterranean Blue,' a 10.3-carat fancy vivid blue diamond sold for $21.5 million during Sotheby's sale of High Jewelry in Geneva on Tuesday. It was not only the top lot of the sale, but it was the marquee item during the series of jewelry auctions held in Geneva. The bidding for the cushion modified brilliant-cut diamond took about two and half minutes from my vantage point watching the live stream. Bidding began at 9 million Swiss Francs and rose to 13 million after the first minute then things got interesting. Potential buyers were quickly reduced to two phone bidders as the price slowly went up to the final hammer price of 15 million Swiss francs. It went to a phone bidder represented by Frank Everett, vice chairman of Jewelry, Americas. Commission and fees boosted the final price to 17.9 million Swiss Francs ($21.5 million). Its estimate was $20 million. There was light applause after the sale. The Mediterranean Blue was crafted from a 31.94 carat rough diamond mined in 2023 from the legendary Cullinan mines of South Africa. The rough was studied for a year and cutting and polishing the gem from the rough took another six months, Sotheby's said. It generated plenty of interest among diamond buyers around the world since its announcement in March. Ahead of its final showing in Geneva, the diamond was unveiled as part of Sotheby's debut exhibition in Abu Dhabi. It was showcased alongside seven other important diamonds and gemstones, collectively worth well over $100 million. The tour of the diamond continued through the Middle East then onto Asia and the United States before ending up in Geneva. 'It is undoubtedly the defining stone of the season and ranks among the top blue diamonds we have sold, Quig Bruning, Sotheby's head of Jewelry, Americas & EMEA, said in a statement. 'To witness the excitement it has generated throughout its global exhibition tour, culminating in today's result, clearly reflects the growing global appetite for rare and impeccable diamonds, and a marked flight to quality among collectors who continue to seek the very best in the world.' The sale of The Mediterranean Blue diamond was the highlight of Sotheby's High Jewelry auction held at the Mandarin Oriental Geneva hotel. The auction of 93 lots achieved 42 million Swiss francs ($50 million) with a 99% sell through by value and 97% by number of lots sold. Colored and colorless diamonds took nine of the top 10 lots. Sotheby's said the auction saw 'extremely strong results for colored diamonds and gemstones and high participation of bidders and buyers from the USA, who were the majority group in both categories.' The number two lot of the sale was a pair of D-flawless diamonds weighing 23.88 and 23.76 carats. This was followed by two more blue diamonds: an oval-shaped 5.83-carat fancy light blue diamond on a ring, which achieved 1.2 million Swiss francs ($1.4 million), beating its estimate; and a 4.05-carat fancy blue heart-shaped diamond pendant necklace that sold for 952,500 Swiss francs ($1.1 million). A 14.72-carat marquise-shaped diamond with D color, VVS2 clarity mounted on a ring between tapered baguette diamond shoulders. The diamond was designed and sold by the renowned Paris jewelry house, M. Gérard. It sold for 660,400 Swiss francs ($786,855). More to come.
